Company research
Satellos Bioscience Inc.
CIK 1421642Updated Nov 9, 2026
Name history
ICO THERAPEUTICS INC · through Sep 10, 2019
MSLE price & chart
Loading TradingView…
NASDAQ:MSLE on TradingView ↗About the company
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem cell signaling that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.
In the news
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development ↗
Satellos to Present at the 31st Annual Congress of the World Muscle Society ↗
Satellos to Participate in Upcoming Investor Conferences ↗
Seeking Alpha
Satellos Bioscience GAAP EPS of -$1.70 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | -24,873,000Source | -20,634,000Source |
| Additional Financial Items | ||
| AdjustmentsForFinanceIncomeUSD | — | 358,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 3,235,000Source | 1,641,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -484,000Source | -1,071,000Source |
| GeneralAndAdministrativeExpenseUSD | 8,033,000Source | 6,039,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 1,160,000Source | 573,000Source |
| ProceedsFromIssuingSharesUSD | — | 30,057,000Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | 13,958,000Source | 32,076,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Additional Financial Items | ||
| ApplicableTaxRatenumber | 0.27Source | 0.27Source |
| BasicEarningsLossPerShareUSD per share | -1.7Source | -2.16Source |
| DilutedEarningsLossPerShareUSD per share | -1.7Source | -2.16Source |
| FinanceIncomeUSD | 1,360,000Source | 1,003,000Source |
| GeneralAndAdministrativeExpenseUSD | 8,033,000Source | 6,039,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | 2,905,000Source |
| IncomeTaxExpenseContinuingOperationsUSD | 172,000Source | — |
| ProfitLossBeforeTaxUSD | -24,701,000Source | -20,634,000Source |
| ProfitLossFromOperatingActivitiesUSD | -26,459,000Source | -20,398,000Source |
| ResearchAndDevelopmentExpenseUSD | 18,426,000Source | 14,359,000Source |
Filing attachments
tm2623194d1_ex99-1.htm · 6-K · 2026-08-14
Exhibit 99.1 Execution Version Satellos Bioscience Inc. Common Shares SALES AGREEMENT August 14, 2026 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Satellos Bioscience Inc., a corporation organized and existing under the laws of Canada (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time durin…
Read attachment ↗tm269531d1_ex4-1.htm · S-8 · 2026-03-27
Exhibit 4.1 Certificate of Amendment Canada Business Corporations Act Certificat de modification Loi canadienne sur les sociétés par actions Satellos Bioscience Inc. Corporate name / Dénomination sociale 1326151-4 Corporation number / Numéro de société I HEREBY CERTIFY that the articles of the above-named corporation are amended under section 178 of the Canada Business Corporations Act as set out in the attached articles of amendment. JE CERTIFIE que les statuts …
Read attachment ↗tm269531d1_ex4-2.htm · S-8 · 2026-03-27
Exhibit 4.2 SatELLOS BIOSCIENCE INC. (the "Corporation") BY-LAW NO. 2 The Corporation is committed to: (i) facilitating an orderly and efficient annual or, where the need arises, special meeting, process; (ii) ensuring that all shareholders receive adequate notice of director nominations and sufficient information with respect to all nominees; (iii) allowing the Corporation and shareholders to evaluate all nominees' qualifications and suitability as a director of the Corporation; and (iv) all…
Read attachment ↗tm269531d1_ex4-3.htm · S-8 · 2026-03-27
Exhibit 4.3 CANADA BUSINESS CORPORATIONS ACT SEE REVERSE FOR CERTAIN DEFINITIONS in the Authorized share structure of the above named Company subject to the Articles of the Company transferable on the Central Securities Register of the Company by the registered holder in person or by attorney duly authorized in writing upon surrender of this certificate properly endorsed. This certificate is not valid unless countersigned by the Transfer Agent and Registrar of the Company. IN WITNESS …
Read attachment ↗tm269531d1_ex99-1.htm · S-8 · 2026-03-27
Exhibit 99.1 SATELLOS BIOSCIENCE INC. (FORMERLY, ICO THERAPEUTICS INC.) SECOND AMENDED AND RESTATED STOCK OPTION PLAN (2023) SECTION 1 GENERAL PROVISIONS 1.1 Definitions For the purpose of this Plan, the following terms shall have the following meanings: (a) "Acceleration Event" has the meaning ascribed thereto in Section 2.8(b); (b) "Administrative Guidelines" means the administrative guidelines relating to this Plan, which may include guidelines rega…
Read attachment ↗tm269531d1_ex99-2.htm · S-8 · 2026-03-27
Exhibit 99.2 SATELLOS BIOSCIENCE INC. OMNIBUS EQUITY INCENTIVE PLAN April 10, 2024 TABLE OF CONTENTS Page ARTICLE 1 PURPOSE 3 1.1 Purpose 3 ARTICLE 2 INTERPRETATION 3 …
Read attachment ↗